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Abstract Chronic obstructive pulmonary disease (COPD) is characterised by limited bronchial reversibility and
chronic neutrophilic inflammation.However, in some cases of COPD, eosinophilic inflammation is present.We investi-
gated the relationship between reversibility to b2-agonist with atopy and neutrophil activation in patients with stable
COPD. For this purpose, 38 outpatients with COPD (mean age: 64 years),12 with asthma (mean age: 51 years) and 13
healthycontrols (mean age: 49 years) weretestedusingincreasingdoses of inhaled salbutamol (upto 3100 mg). According
totheirreversibility,COPDpatientsweredividedintotwogroups: reversible COPD (DFEV1Z12% pred, n= 16) andnon-
reversible COPD (DFEV1o12% pred, n= 22). Atopy, assessed by skin prick, was found at similar frequencies in both
COPD groups.Total serum IgE was higher in COPD patients vs. controls, but did not differ significantly between the
COPD groups.The blood eosinophil count was significantlyhigher in the reversible COPD group than in the non-rever-
sible COPD, and correlated with DFEV1% pred (Rs = 0.54, Po0.05), as well as in asthmatics.The non-reversible COPD
grouphad a higher level of spontaneousneutrophil activation (byreduction of nitroblue tetrazolium) versus controls.We
conclude that airwayreversibility in COPD patients is associatedwiththe degree of blood eosinophilia, butnotwiththe
degree of bloodneutrophil activation.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1485, available online at http://www.sciencedirect.com
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Chronic obstructive pulmonary disease (COPD) and
asthma are de¢ned as chronic non-speci¢c pulmonary
diseases characterised by the presence of bronchial ob-
struction and chronic airway in£ammation. Distinguish-
ing between these diseases is di⁄cult and may be
impossible in some older patients. Traditionally, the de-
gree of reversibility to a bronchodilator has been used
to determine whether a patient is labelled as having
COPD or asthma. In clinical practice, COPD is often
managed as poorly responsive asthma, even though the
nature of in£ammation di¡ers markedly between these
diseases (1).
Airway in£ammation in asthma is characterised by an
increase in CD4+ T lymphocytes, which is often asso-
ciated with tissue and peripheral blood eosinophilia.
Conversely, in£ammation in COPD is dominated by cy-Received 25 June 2002, accepted in revised form 2 December 2002.
Correspondence should be addressed to.B. Sitkauskiene,MD,Clinic of
Pulmonology and Immunology, Kaunas Medical University Hospital,
Eiveniu 2, LT-3007 Kaunas, Lithuania.Fax: +370 37 337504
E-mail: brigita.sit@centras.lttotoxic T lymphocytes and macrophages, often asso-
ciated with a neutrophilia (2,3). However, eosinophilic
in£ammation has been observed in the airways of some
COPD patients (3^7). Moreover, the severity of air£ow
obstruction in such patients was found to correlatewith
the degree of eosinophilia (4^6).
The fact that only approximately 15% of active cigarette
smokers develop COPD suggests that certain patients
are more susceptible (8).Other features that have been
associated with impaired lung function and its progres-
sion to airway obstruction include serum IgE, skin-test
reactivity, eosinophilia and non-speci¢c bronchial re-
sponsiveness (4). As early as1961Orie and colleagues (9)
¢rst illustrated that allergy and increased airways re-
sponsiveness may be factors in the genesis of chronic in-
£ammatory pulmonary disease. This theory became
known as the ‘Dutch hypothesis’ (10). Many studies have
addressed this issue, but theresultshavebeencon£icting
(10,11). Several studies have clearly demonstrated that IgE
and other allergic markers are associated with atopic
asthma (3,12,13). Yet regarding COPD, little advance has
been made since the ’Dutch hypothesis’ was ¢rst pro-
posed. Someprospective studieshave shown that adecline
592 RESPIRATORYMEDICINEin lung function is related to atopy only among current
smokers or in the presence of eosinophilia (14,15). How-
ever, other studies have failed to identify any signi¢cant re-
lation between lung function response and atopy (4,11).
The aim of thepresent study was to evaluatewhether
COPD patients with some b2-agonist reversibility have
increased levels of circulating total IgE, increased levels
of circulating eosinophils, or activated neutrophils.
Moreover, we compared lung function and in£ammatory
markers of COPD patients with the same markers in a
group of asthmatic patients and in control subjects.
METHODS
Subjects
We studied 38 outpatients (aged 38^76 years) who had
been diagnosed clinically as having stable moderate or
severe COPD with smoking history 410 pack/years,
and 12 outpatients with moderate or severe asthma
(aged 34^65 years), non-smokers or ex-smokers r10
pack/years. All patients had clinically diagnosed COPD
or asthma formore than 2 years.COPDwas de¢ned ac-
cording to the criteria of the European Respiratory So-
ciety (16), and asthma was diagnosed according to the
Global Initiative for Asthma (GINA) (17).COPD patients
were divided into two groups according to the results of
a bronchodilatation test: (1) reversible COPD (DFEV1
Z12% pred) and (2) non-reversible COPD (DFEV1o12%
pred).No patients had any respiratory infection, exacer-
bation of disease or changes in treatment during the 2
monthsprior to the study, nor anyknown allergy in their
clinical history. Patients were excluded from the study if
they had other pulmonary or uncontrolled systemic dis-
eases, or had taken systemic corticosteroids in any form
during the previous 2 months. Theophylline and other
antiphlogistic treatments were withdrawn at least 1
month prior to the study. Inhaled steroids were stopped
2 months prior to the study in COPD patients.
Thirteen normal healthy volunteers (aged 38^61 years)
were tested as a control group.
Smoking was investigated and the number of cigarette
pack-years was calculated as the product of the period
of tobacco use (in years) and the average number of ci-
garettes smokedper day.
The study protocol was approved at the Institute for
Biomedical Research, Kaunas University of Medicine,
and each subject gave informed consent.
Spirometry andbronchodilatation protocol
Pulmonary function was tested using a pneumotacho-
metric spirometer ‘Custo vitM’ (Custo Med, Germany)
with subjects in the sittingposition, and thehighest value
of FEV1 and FVC from at least two technically satisfac-
torymanoeuvres di¡ering by less than 5%was recorded.Normal valueswere characterised according toQuanjer
and colleagues (18). Subjects had to avoid the use of long-
acting b2-agonists for Z48h and short-acting b2-ago-
nistsZ8h prior to the test.
Bronchial reversibility was measured using increasing
doses of inhaled salbutamol: 100, 200, 400, 800 and
1600mg, administered every 20min by a spacer device.
Bronchial reversibility to salbutamol was de¢ned as at
least12% improvement in FEV1, providing an absolute in-
crease was greater than or equal to 200ml, as recom-
mended by the American Thoracic Society (19). This
responsewas expressed as:
(1) a percentage of the predicted value of FEV1,
calculated using DFEV1% pred= ((postbronchodilator
FEV1baseline FEV1)/ predicted FEV1) 100;
(2) an absolute value in liters (L), calculated using DFEV1
ml=postbronchodilator FEV1baseline FEV1;
(3) a percentage of baseline FEV1, calculated using
change in DFEV1 % baseline= ((postbronchodilator
FEV1baseline FEV1)/ baseline FEV1) 100.
Allergen skin prick tests
These were performed using the prick method of Pepys
(20) with standard glycerine-preserved allergens: house
dust, Dermatophagoides pteronyssinus, dog hair-dander,
cat hair, mould mix, mixed trees and mixed grasses
(Bayer Corp, Pharmaceutical Div, USA). The reaction
wasmeasured after 20min, subtracting that of the posi-
tive histamine and the negative glycerine control. The
mean wheal size was the arithmetic mean of the reac-
tions to the seven allergens. Atopy was assessed if at
least one allergen yielded a wheal diameter of 3mm and
more than 50% of histaminewheal size (21).
Measurement of total serum
immunoglobulin E (IgE)
Total serum IgE levels were determined from 10ml ve-
nous blood using an enzyme-linked immunosorbent as-
say (Immunotech, Coulter Company, France) and
handled according to themanufacturer’s instructions.
Enumeration of blood eosinophils and
neutrophils
Blood eosinophils and neutrophils were counted with a
Hemoanalizer (ADVIA120, Bayer, Ireland) and expressed
as total number of cells (109/ml). Blood for measure-
ments of serum IgE andperipheral blood cells was taken
before the bronchodilatation test on the same day.
REVERSIBILITYINCOPD 593Determination of neutrophil activation by
reduction of nitroblue tetrazolium (NTB)
Metabolismof neutrophilswas assessedin theNBTassay.
NBT, when incorporated into the phagolysozomes of a
granulocyte, is transformed biochemically into a blue
formazane crystal.Themoremetabolically active the cell
is, themoreNBT is incorporated (22). Spontaneous neu-
trophil activationwas assessed using 0.05 ml heparinised
venous blood with 0.05 ml1% NBT (Sigma, St Louis,MO,
USA) and incubated at 37oC for 30min (23,24). Induced
neutrophil activationwas assessed using stimulation at a
concentration of100 g/ml1E. coli 0111:B4 endotoxin (Sig-
ma) at 37oC for 30 min (25). A thin smear wasmade and
stained for10minwith1%methylenegreen (Sigma).Then,
100 neutrophils were sampled under the oil-immersion
lens of a microscope. Positive neutrophils were de¢ned
as having three ormore formazane crystals (23,24).
Statistics
Statistical analyses were performed using the standard
statistical program (StatView 4.01) by the unpaired Stu-
dent’s t-test. All data were expressed as mean7SEM. A
value of Po0.05 was considered statistically signi¢cant.
RESULTS
Pulmonary function
Basic characteristics of the subjects are summarised in
Table1.COPDpatientswere slightlyolder than asthmatic
patients and control subjects, whereas the mean age of
patients with asthma and controls was similar. Baseline
FEV1was lower in the COPD patients than in asthmatic
patients (Po0.05), and pulmonary function of control
subjectswaswithin normal range. After 3100mgof salbu-0
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FIG. 1. Salbutamol dose-dependent increase in FEV
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(L) in the di¡etamol, 16 COPD patients were considered to be in the
reversible COPD group (FEV1 reversibility: 12-26% from
predicted (median: 17%); range: 220^850ml (median:
500ml)), whereas 22 other COPD patients formed the
non-reversible COPD group (FEV1 reversibility: 1^11%
frompredicted (median: 6%); range: 30^400ml (median:
180ml)) (Fig. 1). Asthmatics had FEV1 reversibility of 13^
40% from predicted (median: 26%); range: 210^1360ml
(median: 810ml) (Table 1). Demographic characteristics
of both COPD groups were similar. Pulmonary function
of both COPD groups did not di¡er signi¢cantly at base-
line, although the reversible COPD group tended to have
slightly higher FEV1 (%) and FEV1/FVCvalues (Table1).
The improvement in FEV1 (%) was already signi¢cant
between the COPD groups after the ¢rst dose of salbu-
tamol (100mg). DFEV1 in asthmatics became signi¢cantly
higher than in the reversible COPD patients only after
administration of the highest dose of salbutamol
(3100mg) (Table 2). Among COPD patients, there was a
signi¢cant correlation between baseline FEV1 (L) and
DFEV1 (L) (Rs=0.46, Po0.01, Spearman’s rank correla-
tion), and between baseline FEV1/FVC and DFEV1 (L)
(Rs=0.36, Po0.05, Spearman’s rank correlation).
Atopy and IgE
Positive skin prick was found at the same frequency in
both COPD groups, and without signi¢cant di¡erence
comparedwith the other two groups (Table1).Themean
wheal size in response to the seven most common aller-
gens was higher in the asthmatics, but not signi¢cantly
di¡erent between the groups.
Thevalue of total serum IgEwas signi¢cantly higher in
theCOPDpatients versus controls (67.7712.1vs17.975.6
IU/ml, Po0.05), and signi¢cantly lower than in patients
with asthma (134.6712.1IU/ml,Po0.05).Between the re-
versible and non-reversible COPD patients, the value ofsible COPD Asthma Control
700µg 1500µg 3100µg
rentgroups.Data are shown asmean7SEM.
TABLE 1. Characteristics of subjects.
Reversible
COPD group
(DFEV1Z12%)
Non-reversible
COPD group
(DFEV1o12%
Asthma
group
Control
group
Numberof subjects 16 22 12 13
Sex,M/Fratio 14/2 20/2 8/4 10/3
Age (years)* 6472 6372 5173 4973
Smoking, (pack-years)* 3378 2875 573 573
FEV1 (% pred)* 4674 3974 5874 12274
FEV1 (L)* 1.3170.13 1.2370.12 1.9372.44 4.0970.25
FEV1/FVCratio (%)* 4273 3873 5973 8272
Atopy (%)w 38 36 58 46
Meanwheal size (mm)* z 0.870.3 0.670.2 1.170.3 0.570.2
Bloodneutrophils (x109/ml)* 3.8770.29 4.1870.29 3.5970.31 3.6470.30
*Values aremean7SEM.
wValues are n (%).
zMeanof wheal size in response to sevenused allergens.
TABLE 2. Characteristics of response to salbutamol
P-value
Total dose of
salbutamol (mg)
FEV1 Reversible
COPD (R)
Nonreversible
COPD (NR)
Asthma
(A)
Control
(C)
R/NR R/A R/C NR/A NR/C A/C
100 % pred 9.571.4 2.270.6 11.771.8 1.372.7 o0.001 NS o0.01 o0.001 NS o0.01
% basel 21.273.2 6.571.8 22.373.8 1.672.3 o0.001 NS o0.001 o0.001 NS o0.001
l 0.2870.05 0.0770.02 0.3470.05 0.0570.09 o0.001 NS o0.05 o0.001 NS o0.01
300 % pred 12.371.5 3.870.8 14.571.9 3.872.5 o0.001 NS o0.01 o0.001 NS o0.01
% basel 28.073.5 11.472.2 27.274.1 3.872.4 o0.001 NS o0.001 o0.001 o0.05 o0.001
l 0.3670.06 0.1370.03 0.4670.06 0.1470.08 o0.001 NS o0.05 o0.001 NS o0.01
700 % pred 14.671.5 5.070.8 18.472.8 6.272.3 o0.001 NS o0.01 o0.001 NS o0.01
% basel 33.673.4 14.572.9 34.475.5 5.672.4 o0.001 NS o0.001 o0.01 o0.05 o0.001
l 0.4370.06 0.1570.03 0.5870.09 0.2170.08 o0.001 NS o0.05 o0.001 NS o0.01
1500 % pred 16.371.3 5.270.8 22.273.2 5.072.5 o0.001 NS o0.001 o0.001 NS o0.001
% basel 38.174.0 14.7 2.2 41.576.4 4.872.5 o0.001 NS o0.001 o0.001 o0.01 o0.001
l 0.4770.05 0.16 0.03 0.6970.10 0.1870.08 o0.001 o0.05 o0.01 o0.001 NS o0.001
3100 % pred 17.471.4 5.770.9 25.572.4 5.072.5 o0.001 o0.01 o0.001 o0.001 NS o0.001
% basel 40.874.1 15.472.3 48.776.7 4.872.6 o0.001 NS o0.001 o0.001 o0.01 o0.001
l 0.5070.05 0.1870.03 0.8170.08 0.1870.08 o0.001 o0.01 o0.01 o0.001 NS o0.001
Results are shown asmean7SEM.
De¢nition of abbreviation:NS = not signi¢cant
594 RESPIRATORYMEDICINEserum total IgE did not di¡er signi¢cantly (P=0.09) (Fig.
2).Therewas no correlation between serum total IgE le-
vel and DFEV1 (%), or total IgE and smoking history
(pack/yrs).
Peripheral blood eosinophils
Peripheral blood eosinophil counts were higher in the
COPD patients and asthmatics than in the control sub-
jects, and were signi¢cantly greater in the reversibleCOPD group vs. the non-reversible COPD group (Fig.
3).The total number of peripheral blood eosinophils cor-
related signi¢cantly with the increase in FEV1 (%) in the
reversible COPD patients and asthmatics (Fig. 4).
Activation of neutrophils
The absolute number of neutrophils in peripheral blood
was not signi¢cantly di¡erent in the studied groups
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FIG. 3. Eosinophil cell counts in peripheral blood in the di¡erent groups.Data are shown asmean7SEM. *Po0.05, *Po0.01versus
the controlgroup.
REVERSIBILITYINCOPD 595(Table1).Data obtained from theNTB test revealed that
the mean percentage of spontaneous activated neutro-
phils in COPD patients was signi¢cantly higher com-
pared with the control group (23.672.2 vs. 16.071.4%
of neutrophils, Po0.05), a signi¢cance that exists due to
an increase in the percentage of activated neutrophils in
the non-reversible COPD group (Fig. 5). The value of
spontaneous activated neutrophils in patients with asth-
ma did not di¡er from that in controls. After stimulation
with E. coli endotoxin, the percentage of activated
neutrophils in peripheral blood increased signi¢cantly in
asthmatics, and even more so in the COPD groups vs.
control subjects (Fig. 5). However, there was no signi¢-cant di¡erence in the mean percentage of spontaneous
or induced neutrophil activation between the reversible
and non-reversible COPD group.No signi¢cant relation-
ship was detected between the activation of neutrophils
by NTB reduction and salbutamol-induced DFEV1 (%;
Rs=0.1, P=0.6), or with smoking history (pack-years;
Rs=0.3, P=0.07).
DISCUSSION
Our study was designed to evaluate whether airway re-
versibility inCOPDpatients is amountedwithperipheral
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596 RESPIRATORYMEDICINEmarkers of atopy, eosinophilia, or neutrophil activation.
We found that more than one-third of patients with
stable COPD had partial reversible airway obstruction.
This group had a higher count of eosinophils in compari-son with normal subjects. Reversibility to a b2-agonist
also closely correlated with the absolute number
of eosinophils in peripheral blood. COPD patients
with non-reversible airway obstruction showed
REVERSIBILITYINCOPD 597higher degree of neutrophil activation vs. control
subjects.
There is still no agreement on how a bronchodilator
response should be expressed in an ideal way. In our
study, the improvement in FEV1 was indicated by three
di¡erent expressions of bronchodilator response: D%
predicted FEV1,D absolute FEV1 (L) andD% FEV1ofbase-
line.However, Brand and colleagues (26) have suggested
that DFEV1% pred is the most useful method of expres-
sing bronchodilator response for clinical and research
purposes, which has also been argued by Quadrelli and
colleagues (27).The result from our study does not dis-
agree with these conclusions, although the results from
all three ways of evaluating reversibility lead to similar
conclusions in our hands.
The degree of reversibility in COPD patients is gener-
ally very limited.However, it has been shown that up to
30%ofpatientswith stableCOPDundergo an increase in
FEV1of more than15% frombaseline after inhalation of a
short-acting b2-agonist after single test, andup to 70% of
patients during serial testing (28). In our study, 16 of 38
COPD patients (42%) showed an improvement in FEV1%
of more than 12% using increasing doses of salbutamol
(up to 3100mg).This ¢nding supports the argument that
the absence of a bronchodilator response during a single
test with a common dose of salbutamol does not justify
withholding bronchodilator therapy.
In our study, atopy was de¢nedby skin prick test.De-
spite the exclusion of subjects with a known history of
allergy, positive skin prick was found in 27 of 63 tested
subjects. Previous studies of allergy and lung function
have been inconsistent. A prospective study by Frew
and colleagues (14) found a relationship between atopy
and decline in lung function among current smokers. In
another analysis, FEV1was associated with atopy only in
the presence of eosinophilia in subjects younger than 55
years of age (15). In our study, skin test reactivity appears
not to be related to airway obstruction reversibility as in
many other studies (4,11,15).
The relationship between serum IgE and lung function
in COPD patients is not clear.We found signi¢cantly in-
creased serum total IgE in COPD patients compared
with healthy subjects, but this level was still signi¢cantly
lower than in asthmatics. In two previously published
studies (29, 30), a signi¢cant relationship between total
IgE and degree of tobacco smoking has been shown, sug-
gesting that the increase in IgE is partly due to tobacco
smoking. It has also been suggested that smoking stimu-
lates interleukin-4 production (29).However, we did not
¢nd a signi¢cantly raised serum total IgE level in the re-
versible COPD patients, although a tendency was seen
(P=0.09).Thus, there is no evidence that total IgE is re-
lated to reversibility, although such a correlation cannot
be excluded (31).
One important ¢nding in our study is that patients
with reversible COPD had signi¢cantly more peripheralblood eosinophils. Furthermore, in this group of
patients, the eosinophil count signi¢cantly correlated to
the percentage improvement of FEV1 induced by
salbutamol. Moreover, this relationship was similar in
COPD and asthma patients. This ¢nding is in agree-
ment with those of Dahlen and colleagues, who
found a signi¢cant relationship between the change in
eosinophil markers and the improvement in lung
function in non-smokers or short-term smokers
following the emergency treatment of obstructive
pulmonary disease (32). Earlier, Chanez and colleagues
(5) have reported that the percentage of reversibility
to an oral corticosteroid test correlates with the
number of eosinophils in the airways of COPD patients.
Together, these ¢ndings suggest that eosinophils may be
involved in bronchial smooth muscle contractility in
COPD.
The percentage of active neutrophils was greater in
the non-reversible COPD group compared with
the control group.This ¢nding supports the current the-
ory that neutrophils may be involved in forms of more
emphysematic COPD without reversibility (33,34). This
is further supported by a study of 60-year-old ‘healthy’
smokers and never-smokers, showing that neutrophil ac-
tivation in the smoking population was related to lung
function deterioration and early emphysematous
changes (35). In our study we documented a weak
(Rs=0.3) but statistically not signi¢cant relationship be-
tween the neutrophil activation by NTB test and smok-
ing history in COPD.
Our data support the ‘Dutch Hypothesis’, (9) arguing
that allergic sensitisation could be a factor in a COPD
group with b2-agonist reversibility, but does not appear
to apply to a non-reversible form of COPD.Thus,COPD
patients with b2-agonist reversibility and ongoing eosi-
nophilic in£ammation may represent an intermediate
group of patients, between asthma and non-reversible
COPD, which may have implication for the choice of
therapy.
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